← brief for 2026-10-11 · Slowing decline

Sotagliflozin Reprograms Hepatic Lipid Metabolism and Attenuates Atherosclerosis Beyond Empagliflozin in CKM Mice.

Preprint D Not peer reviewed Preclinical

Key takeaways

This study looked at a heart and kidney drug in mice. It found the drug changed how the liver handles fat. It also seemed to slow the buildup of plaque in the arteries. This was in animals, not people yet.

Who did this work

Saum K · Sim J · Zeng L · Steward C · Kayampilly P · Dixon A · Singh A · Abdel-Latif A · Pennathur S

Source

Preprint · PubMed, the drug frontier · 2026 Oct 1
https://pubmed.ncbi.nlm.nih.gov/42856399/